SCHEMBL6725682

SCHEMBL6725682

NS(=O)(=O)c1ccc(-c2ccccc2-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.77
PTGS2 P35354 10/20 0.67
PTGS1 P23219 7/20 0.67
CA12 O43570 6/20 0.57
CA2 P00918 6/20 0.57
CA9 Q16790 6/20 0.57
CA1 P00915 5/20 0.57
MAPT P10636 1/20 0.54
DRD1 P21728 1/20 0.53
CYP2C9 P11712 1/20 0.51
PTGES2 Q9H7Z7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6732634 0.89 PTGS1 (0.61) KIF11PTGS2PTGS1CA12CA2
SCHEMBL6724538 0.86 PTGS1 (0.58) KIF11PTGS2PTGS1CA12CA2
SCHEMBL792636 0.85 KIF11 (0.88) KIF11PTGS2PTGS1CA12CA2
SCHEMBL8659835 0.83 KIF11 (0.53) KIF11PTGS2PTGS1PTGES2
SCHEMBL6732105 0.83 KIF11 (0.72) KIF11PTGS2PTGS1
Hydrochloric Acid SCHEMBL29970350 0.83 KIF11 (0.84) KIF11PTGS2PTGS1CA12CA2
Iodide SCHEMBL28551007 0.83 KIF11 (0.84) KIF11PTGS2PTGS1CA12CA2
SCHEMBL9492276 0.83 KIF11 (0.84) KIF11PTGS2PTGS1CA12CA2
SCHEMBL6724113 0.83 PTGS1 (0.62) KIF11PTGS2PTGS1CA12CA2
SCHEMBL2567683 0.83 KIF11 (0.56) KIF11PTGS2PTGS1PTGES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2004-08-12 US claimed
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. (US) 2002-11-14 US claimed
EP-0794942-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2000-05-31 EP claimed
EP-0794942-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-09-17 EP claimed
WO-1996016934-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-06-06 WO claimed
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2004-08-12 US disclosed
US-6677488-B2 AS AN EXAMPLE, 4-(4,5-DIFLUORO-2-(3-CHLORO-4-FLUOROPHENYL) PHENYLBENZENESULFONAMIDE; ANTIARTHRITIC AGENTS; ANTIPYRETICS; ANALGESICS; PROSTAGLANDIN INHIBITORS; SIDE EFFECT REDUCTION G.D. SEARLE & CO. 2004-01-13 US disclosed
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation G.D. SEARLE & CO. (US) 2002-11-14 US disclosed
EP-0794942-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2000-05-31 EP disclosed
EP-0794942-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-09-17 EP disclosed
WO-1996016934-A1 SUBSTITUTED BIPHENYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169206-A1 Substituted biphenyl compounds for the treatment of inflammation AHR, ARNT, GPBAR1 KIF11 4637/4885PTGS2 379/4885PTGS1 292/4885
US-20040158074-A1 Substituted biphenyl compounds for the treatment of inflammation AHR, ARNT, GPBAR1 KIF11 4637/4885PTGS2 379/4885PTGS1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.